carbenoxolone sodium has been researched along with Glucose Intolerance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
| Acharya, V; Ayyalasomayajula, V; Koppala, SR; Nemani, H; Ponday, LR; Pothana, S; Prasad Sakamuri, SS; Prathipati, VK; Putcha, UK; Sukapaka, M; Veetill, GN | 1 |
2 other study(ies) available for carbenoxolone sodium and Glucose Intolerance
| Article | Year |
|---|---|
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |
Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipocytes; Adipose Tissue; Adrenal Glands; Animals; Body Composition; Carbenoxolone; Cholesterol, HDL; Corticosterone; Eating; Enzyme Inhibitors; Fibrosis; Gene Expression Regulation; Glucose Intolerance; Glycogen; Hypertrophy; Liver; Male; Metabolic Syndrome; Obesity; Organ Size; Rats; Signal Transduction; Thinness; Triglycerides | 2012 |